- Email: [email protected]
P.2.f.001 The effect of antidepressant treatment on quality of life in patients with depressive disorders
S396
P.2.f. Mood disorders and treatment − Treatment (clinical)
P.2.f. Mood disorders and treatment − Treatment (clinical) P.2.f.001 The effect of antidepressant treatment on quality of life in patients with depressive disorders H.C. Kim1 ° , S.K. Hwang1 , M.J. Lee2 , H.J. Jo3 , T.H. Jun4 , M.S. Lee5 , J.M. Kim6 , H.W. Yim7 , J.B. Kim1 1 Keimyung University School of Medicine, Dept of Psychiatry, Daegu, South-Korea; 2 Keimyung University School of Medicine, Dept of Family Medicine, Daegu, South-Korea; 3 Youngnam University, Dept of Psychology, Daegu, South-Korea; 4 Catholic University School of Medicine, Dept of Psychiatry, Seoul, South-Korea; 5 Korea University School of Medicine, Dept of Psychiatry, Seoul, South-Korea; 6 Chonnam National University School of Medicine, Dept of Psychiatry, Gwangju, South-Korea; 7 Catholic University School of Medicine, Dept of Preventive Medicine, Seoul, South-Korea Objectives: Depressive disorders are severe or persistent enough to interfere with daily functioning and quality of life (QoL). Placebo-controlled studies that have reported significant effects of antidepressants treatment on QoL outcome measures [1−3]. This study was aimed to evaluate the effect of long-term antidepressant treatment on QoL in patients with depressive disorders. Methods: We obtained the data from 317 depressive patients who entered the Clinical Research Center for Depression (CRESCEND) study and completed 6 months follow-up period. The CRESCEND study is a long-term (phase 1, 1-year; phase 2, 8-year) observa-tional collaborative prospective cohort study of clinical out-comes in participants with depressive disorders. The inclusion criteria for the study participants were (1) an age over 7 years and (2) a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), diagnosis of major depressive disorder, dysthymic disorder, or depressive disorder, not other specified, as determined by a DSM-IV-based structured clinical interview. The participants of this study were in- and outpatients that visited the psychiatric departments of 16 university hospitals and two general hospitals, distributed throughout South Korea from January 2006 to August 2008. Patients were divided into remission and non-remission groups, according to the scores of Korean version of Hamilton Depression Rating Scale (K-HDRS). Remission group was defined as a K-HDRS score 7 at 6 months follow-up. The 26-item abbreviated Korean version of the World Health Organization Quality of Life Scale Abbreviated Version (K-WHOQOL-BREF) was used for the assessment of QOL. Results: During the follow-up period of 6 months, 147 patients (47%) went into remission. Major depressive disorder was significantly more common in non-remission group than in remission group. There were no significant differences in sociodemographic data and types of antidepressants between remission and non-remission groups. The baseline score of K-HDRS before antidepressant treatment was significantly higher in nonremission group than in remission group. The baseline score of K-WHOQOL-BREF before antidepressant treatment was significantly higher in remission group than in non-remission group. Regardless of group, depressive symptoms were negatively correlated with all 4 domain scores of the WHOQOL-BREF before antidepressant treatment.
Significant improvements of 4 domain scores of the WHOQOLBREF were observed in remission group after 6 months of antidepressant treatment. Significant improvements of 3 domain scores of the WHOQOLBREF except social relationships domain were observed in non-remission group after 6 months of antidepressant treatment. Repeated-measures ANOVA of 4 domain scores of the K-WHOQOL-BREF showed a significant group-by-time interaction with the remission group showing significantly more improvements in 4 domain scores of the K-WHOQOL-BREF over the 6 months than the non-remission group. Conclusions: This study showed that subjective improvement in QoL can be achieved by antidepressant treatment whether patients with depressive disorders were remitted or not after 6 months of antidepressant treatment. References [1] Lydiard RB, et al., 1997. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry, 58(11), 484–491. [2] Dubini A, et al., 1997. Noradrenaline-selective versus serotoninselective antidepressant therapy: differential effects on social functioning. J Psychopharmacol, 11(4 Suppl), S17−23. [3] Lenderking WR, et al., 1999. The effects of venlafaxine on social activity level in depressed outpatients. J Clin Psychiatry, 60(3), 157– 163.
P.2.f.002 Effect of brain volume-related single nucleotide polymorphisms (SNPs) of glycogen synthase kinase 3 (GSK3)-beta gene on SSRI/SNRI treatment response in major depressive disorder M. Kato1 ° , S. Nonen2 , Y. Takekita1 , J. Azuma2 , T. Kinoshita1 Medical University, Department of Neuropsychiatry, Osaka, Japan; 2 Hyogo University of Health Science, School of Pharmacy, Hyogo, Japan
1 Kansai
Introduction: Glycogen synthase kinase-3 (GSK3) is a broadly influential enzyme in neural systems that modulates many aspects of neuronal function, such as gene expression, neurogenesis, and synaptic plasticity. Out of two isoforms of GSK protein, GSK3B expressed in all brain regions and involved in the pathogenesis of major depressive disorder (MDD) and that inhibition of GSK3B activity may play a role in the therapeutic effects of antidepressants. Recently, two SNPs, rs6438552 and rs12630592, were reported to be associated with brain structural change in MDD patient but not in healthy control [1]. This suggests that these two SNPs could have a considerable role in developing to and recovering from MDD. Therefore we examined the possible association of rs6438552 and rs12630592 in SSRI efficacy in MDD subjects followed for 6 weeks. Method: 143 Japanese patients with major depression, consecutively admitted to the Department of Neuropsychiatry at Kansai Medical University, Osaka were included in this study as a part of pharmacogenetic randomized controlled study of SSRI/ SNRI. The clinical response was evaluated using the Hamilton Rating Scale for Depression (HAM-D) assessed at each visit for 6 week. The rs6438552G>A and rs12630592T>G variants in GSK3B gene were determined. Single genotype associations with HAM-D scores change (%) over time were analyzed by repeated measures analysis of variance with factors of necessity included in the model as covariates. Response rate among variants was
P.2.f. Mood disorders and treatment − Treatment (clinical)
P.2.f. Mood disorders and treatment − Treatment (clinical) P.2.f.001 The effect of antidepressant treatment on quality of life in patients with depressive disorders H.C. Kim1 ° , S.K. Hwang1 , M.J. Lee2 , H.J. Jo3 , T.H. Jun4 , M.S. Lee5 , J.M. Kim6 , H.W. Yim7 , J.B. Kim1 1 Keimyung University School of Medicine, Dept of Psychiatry, Daegu, South-Korea; 2 Keimyung University School of Medicine, Dept of Family Medicine, Daegu, South-Korea; 3 Youngnam University, Dept of Psychology, Daegu, South-Korea; 4 Catholic University School of Medicine, Dept of Psychiatry, Seoul, South-Korea; 5 Korea University School of Medicine, Dept of Psychiatry, Seoul, South-Korea; 6 Chonnam National University School of Medicine, Dept of Psychiatry, Gwangju, South-Korea; 7 Catholic University School of Medicine, Dept of Preventive Medicine, Seoul, South-Korea Objectives: Depressive disorders are severe or persistent enough to interfere with daily functioning and quality of life (QoL). Placebo-controlled studies that have reported significant effects of antidepressants treatment on QoL outcome measures [1−3]. This study was aimed to evaluate the effect of long-term antidepressant treatment on QoL in patients with depressive disorders. Methods: We obtained the data from 317 depressive patients who entered the Clinical Research Center for Depression (CRESCEND) study and completed 6 months follow-up period. The CRESCEND study is a long-term (phase 1, 1-year; phase 2, 8-year) observa-tional collaborative prospective cohort study of clinical out-comes in participants with depressive disorders. The inclusion criteria for the study participants were (1) an age over 7 years and (2) a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), diagnosis of major depressive disorder, dysthymic disorder, or depressive disorder, not other specified, as determined by a DSM-IV-based structured clinical interview. The participants of this study were in- and outpatients that visited the psychiatric departments of 16 university hospitals and two general hospitals, distributed throughout South Korea from January 2006 to August 2008. Patients were divided into remission and non-remission groups, according to the scores of Korean version of Hamilton Depression Rating Scale (K-HDRS). Remission group was defined as a K-HDRS score 7 at 6 months follow-up. The 26-item abbreviated Korean version of the World Health Organization Quality of Life Scale Abbreviated Version (K-WHOQOL-BREF) was used for the assessment of QOL. Results: During the follow-up period of 6 months, 147 patients (47%) went into remission. Major depressive disorder was significantly more common in non-remission group than in remission group. There were no significant differences in sociodemographic data and types of antidepressants between remission and non-remission groups. The baseline score of K-HDRS before antidepressant treatment was significantly higher in nonremission group than in remission group. The baseline score of K-WHOQOL-BREF before antidepressant treatment was significantly higher in remission group than in non-remission group. Regardless of group, depressive symptoms were negatively correlated with all 4 domain scores of the WHOQOL-BREF before antidepressant treatment.
Significant improvements of 4 domain scores of the WHOQOLBREF were observed in remission group after 6 months of antidepressant treatment. Significant improvements of 3 domain scores of the WHOQOLBREF except social relationships domain were observed in non-remission group after 6 months of antidepressant treatment. Repeated-measures ANOVA of 4 domain scores of the K-WHOQOL-BREF showed a significant group-by-time interaction with the remission group showing significantly more improvements in 4 domain scores of the K-WHOQOL-BREF over the 6 months than the non-remission group. Conclusions: This study showed that subjective improvement in QoL can be achieved by antidepressant treatment whether patients with depressive disorders were remitted or not after 6 months of antidepressant treatment. References [1] Lydiard RB, et al., 1997. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry, 58(11), 484–491. [2] Dubini A, et al., 1997. Noradrenaline-selective versus serotoninselective antidepressant therapy: differential effects on social functioning. J Psychopharmacol, 11(4 Suppl), S17−23. [3] Lenderking WR, et al., 1999. The effects of venlafaxine on social activity level in depressed outpatients. J Clin Psychiatry, 60(3), 157– 163.
P.2.f.002 Effect of brain volume-related single nucleotide polymorphisms (SNPs) of glycogen synthase kinase 3 (GSK3)-beta gene on SSRI/SNRI treatment response in major depressive disorder M. Kato1 ° , S. Nonen2 , Y. Takekita1 , J. Azuma2 , T. Kinoshita1 Medical University, Department of Neuropsychiatry, Osaka, Japan; 2 Hyogo University of Health Science, School of Pharmacy, Hyogo, Japan
1 Kansai
Introduction: Glycogen synthase kinase-3 (GSK3) is a broadly influential enzyme in neural systems that modulates many aspects of neuronal function, such as gene expression, neurogenesis, and synaptic plasticity. Out of two isoforms of GSK protein, GSK3B expressed in all brain regions and involved in the pathogenesis of major depressive disorder (MDD) and that inhibition of GSK3B activity may play a role in the therapeutic effects of antidepressants. Recently, two SNPs, rs6438552 and rs12630592, were reported to be associated with brain structural change in MDD patient but not in healthy control [1]. This suggests that these two SNPs could have a considerable role in developing to and recovering from MDD. Therefore we examined the possible association of rs6438552 and rs12630592 in SSRI efficacy in MDD subjects followed for 6 weeks. Method: 143 Japanese patients with major depression, consecutively admitted to the Department of Neuropsychiatry at Kansai Medical University, Osaka were included in this study as a part of pharmacogenetic randomized controlled study of SSRI/ SNRI. The clinical response was evaluated using the Hamilton Rating Scale for Depression (HAM-D) assessed at each visit for 6 week. The rs6438552G>A and rs12630592T>G variants in GSK3B gene were determined. Single genotype associations with HAM-D scores change (%) over time were analyzed by repeated measures analysis of variance with factors of necessity included in the model as covariates. Response rate among variants was